Travoprost/timolol

Drug Profile

Travoprost/timolol

Alternative Names: 0.004% travoprost/0.5% timolol; DuoTrav; DuoTrav APS; DuoTrav® PQ; DuoTrav™ BAK; Extravan; Timolol/travoprost; Travoprost + Timolol Fixed Combination; TTFC

Latest Information Update: 07 Apr 2017

Price : $50

At a glance

  • Originator Alcon
  • Class Antiglaucomas; Antihypertensives; Propanolamines; Prostaglandins; Thiadiazoles
  • Mechanism of Action Beta-adrenergic receptor antagonists; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma

Most Recent Events

  • 27 Jan 2017 Novartis has patent protection for travoprost/timolol in Europe and Japan (Novartis 20-F filed in 2017)
  • 13 Apr 2015 No recent reports on development identified - Preregistration for Glaucoma in USA (Ophthalmic)
  • 08 Apr 2011 Novartis completes acquisition of Alcon
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top